Under the extended contract, the dedicated R&D center, ‘Syngene Amgen Research and Development Center’ (SARC), will continue to conduct drug discovery and development projects as part of Amgen’s global R&D program
Syngene International today announced the extension of its long-standing multi-discipline research collaboration with Amgen Inc, one of the world’s leading biotechnology companies.
The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development.
In addition to operating the existing Syngene Amgen R&D Center (SARC), under the new contract, Syngene will also build and operate a dedicated laboratory which will enable R&D project acceleration.
The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. In addition to operating the existing Syngene Amgen R&D Center (SARC), under the new contract, Syngene will also build and operate a dedicated laboratory which will enable R&D project acceleration.
Jonathan Hunt, CEO and Managing Director, Syngene International Ltd., said, “While SARC was established in 2016, our collaboration with Amgen dates back to 2012. During this time, we have partnered on research and development to address some of the most serious diseases in the world. We have progressively expanded our areas of collaboration, co authored research papers on novel science and supported the advancement of multiple development projects, while adhering to global standards of quality and safety. We are proud to have played a role in advancing molecules that are making a difference to patients around the world today. We are delighted with our joint commitment to not only extend the term of this partnership but also add a new state-of-the-art facility to the collaboration.”
“Amgen is pleased with the success of the long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials,” said Margaret Chu-Moyer, Ph.D., Vice President of Research and Head of Chemistry, Characterization & Technology at Amgen. “We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.”
SARC was established in 2016 and Syngene announced expansion of the original dedicated centre in 2017. It currently consists of 60,000 sq. ft. of floor space and a dedicated team of multi-disciplinary Syngene scientists who work closely with Amgen researchers around the world on the discovery and development of innovative medicines.
About Syngene International
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing organization providing scientific services – from early discovery to commercial supply. Our innovative capabilities for novel molecular entities (NMEs) cater to a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies.
About Amgen Inc.
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world’s largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. Amgen’s Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
In 2018, the company’s largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA. Amgen sponsors the Tour of California